title: The Antitumor Effect of Gekko Sulfated Glycopeptide by Inhibiting bFGF-Induced Lymphangiogenesis.
abstract: Objective. To study the antilymphangiogenesis effect of Gekko Sulfated Glycopeptide (GSPP) on human lymphatic endothelial cells (hLECs). Methods. MTS was conducted to confirm the antiproliferation effect of GSPP on hLECs; flow cytometry was employed to detect hLECs cycle distribution; the antimigration effect of GSPP on hLECs was investigated by wound healing experiment and transwell experiment; tube formation assay was used to examine its inhibitory effect on the lymphangiogenesis; western blotting was conducted to detect the expression of extracellular signal-regulated kinase1/2 (Erk1/2) and p-Erk1/2 after GSPP and basic fibroblast growth factor (bFGF) treatment. Nude mice models were established to investigate the antitumor effect of GSPP in vivo. Decreased lymphangiogenesis caused by GSPP in vivo was verified by immunohistochemical staining. Results. In vitro, GSPP (10 μg/mL, 100 μg/mL) significantly inhibited bFGF-induced hLECs proliferation, migration, and tube-like structure formation (P < 0.05) and antagonized the phosphorylation activation of Erk1/2 induced by bFGF. In vivo, GSPP treatment (200 mg/kg/d) not only inhibited the growth of colon carcinoma, but also inhibited the tumor lymphangiogenesis. Conclusion. GSPP possesses the antitumor ability by inhibiting bFGF-inducing lymphangiogenesis in vitro and in vivo, which may further inhibit tumor lymphatic metastasis.
authors.affiliation: Zhong-Shan-Men In-Patient Department, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Huan-Hu-Xi Road, He-Xi District, Tianjin 300060, China.
authors.forename: Xiu-Li
authors.initials: XL
authors.lastname: Ding
authors.affiliation: Department of Radiotherapy, The Second Affiliated Hospital of Tianjin Medical University, Ping-Jiang Road, He-Xi District, Tianjin 300060, China.
authors.forename: Ya-Nan
authors.initials: YN
authors.lastname: Man
authors.affiliation: Zhong-Shan-Men In-Patient Department, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Huan-Hu-Xi Road, He-Xi District, Tianjin 300060, China.
authors.forename: Jian
authors.initials: J
authors.lastname: Hao
authors.affiliation: Zhong-Shan-Men In-Patient Department, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Huan-Hu-Xi Road, He-Xi District, Tianjin 300060, China.
authors.forename: Cui-Hong
authors.initials: CH
authors.lastname: Zhu
authors.affiliation: Zhong-Shan-Men In-Patient Department, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Huan-Hu-Xi Road, He-Xi District, Tianjin 300060, China.
authors.forename: Chang
authors.initials: C
authors.lastname: Liu
authors.affiliation: Zhong-Shan-Men In-Patient Department, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Huan-Hu-Xi Road, He-Xi District, Tianjin 300060, China.
authors.forename: Xue
authors.initials: X
authors.lastname: Yang
authors.affiliation: Zhong-Shan-Men In-Patient Department, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Huan-Hu-Xi Road, He-Xi District, Tianjin 300060, China.
authors.forename: Xiong-Zhi
authors.identifier: 0000-0001-8277-5667
authors.initials: XZ
authors.lastname: Wu
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage; D045744:Cell Line, Tumor; D016222:Fibroblast Growth Factor 2 / Q000378:metabolism; D006801:Humans; D042583:Lymphangiogenesis / Q000187:drug effects*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D011134:Polysaccharides / Q000008:administration & dosage*; D016896:Treatment Outcome; D047368:Tumor Burden / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D011134:Polysaccharides; C519079:gepsin; D016222:Fibroblast Growth Factor 2